# Nora Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nora-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Saint Lambert, Canada
- Website: www.norapharma.ca
- Total disclosed funding: $25M
- Latest round: Series A (Oct 23, 2008)
- Investors on record: 3

## About

Nora Pharmaceuticals is a Canadian pharmaceutical company specializing in the distribution of generic medications, enhancing accessibility to affordable healthcare across Canada.Founded in 2017, Nora Pharmaceuticals is based in Saint Lambert, Canada. The company focuses on distributing generic drugs nationally and has completed 2 deals to date. In October 2022, it was acquired by Sunshine Biopharma Inc. in a TRADE SALE valued at CAD 30 million. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc.Nora Pharma is dedicated to providing a range of high-quality generic medications designed to improve patient access to healthcare solutions. The company serves various therapeutic areas, supporting healthcare professionals and patients with effective treatment options. Its products are primarily distributed to hospitals, pharmacies, and healthcare establishments throughout Canada, fostering partnerships with practitioners to ensure reliable access to medications.Nora Pharma generates revenue through the distribution of its generic pharmaceuticals via B2B transactions with healthcare providers and pharmacies. The company supplies medications directly to facilities, facilitating timely access to essential drugs. Revenue is derived from product sales, including its recently approved biosimilar, NIOPEG®, aligning with the company's commitment to expanding its product portfolio while maintaining competitive pricing and regulatory compliance.Following its acquisition in October 2022, Nora Pharmaceuticals plans to leverage its resources to innovate and expand its product offerings, including the development of new generic medications. The recent funding of CAD 30 million will be utilized to enhance R&D capabilities and support product launches. The company also aims to penetrate additional Canadian healthcare markets and establish partnerships that could enable broader distribution of its high-quality medications.

## Funding rounds

- Series A, Oct 23, 2008, $25M — Burrill & Company, Prospect Venture Partners, Vivo Capital

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A